Related Experiment Video
Updated: Aug 2, 2026

Non-Invasive Model of Neuropathogenic Escherichia coli Infection in the Neonatal Rat
Published on: October 29, 2014
Clinical experience with Escherichia coli rHuGM-CSF
Abstract:
The use of rHuGM-CSF has resulted in patient benefit as shown by reduced infections (MDS and AA), reduced days in intensive care (ABM transplant), better adherence to cancer chemotherapy protocols, and the ability to use full doses of antiviral drugs in AIDS and cytomegalovirus retinitis. The adverse reactions are significant when high doses are used, therefore high doses should be avoided (there is a plateau in the dose-effective biological responses). At recommended doses, GM-CSF is well tolerated and is a valuable adjunctive therapy in the management of patients with conditions of dysmyelopoiesis and myeloid hypoplasia associated with myelotoxic therapy, or after bone marrow transplantation.
Insights
Recombinant human granulocyte-macrophage colony-stimulating factor (rHuGM-CSF) reduces infections and intensive care days, improving chemotherapy adherence. Recommended doses are well-tolerated and beneficial for myeloid disorders and post-transplant care.
Area of Science:
- Hematology
- Oncology
- Immunology
Background:
- Myelodysplastic syndromes (MDS) and aplastic anemia (AA) are associated with increased infection risk.
- Bone marrow transplantation (BMT) can lead to prolonged intensive care unit (ICU) stays.
- Cancer chemotherapy and certain viral infections (e.g., AIDS, cytomegalovirus retinitis) can cause myeloid hypoplasia.
Purpose of the Study:
- To evaluate the clinical benefits of recombinant human granulocyte-macrophage colony-stimulating factor (rHuGM-CSF).
- To assess the safety and efficacy of rHuGM-CSF in patients with myelodysplastic syndromes, aplastic anemia, post-bone marrow transplant, and viral infections.
- To determine optimal dosing to maximize therapeutic effects while minimizing adverse reactions.
Main Methods:
- Clinical use of rHuGM-CSF in patients with various hematologic and oncologic conditions.
- Monitoring of infection rates, intensive care unit (ICU) days, chemotherapy adherence, and antiviral drug efficacy.
- Dose-ranging studies to identify effective and safe dosage levels.
Main Results:
- rHuGM-CSF significantly reduced infections in patients with MDS and AA.
- Reduced ICU days were observed in allogeneic bone marrow transplant (ABM transplant) recipients.
- Improved adherence to chemotherapy protocols and enhanced efficacy of antiviral therapies were noted.
Conclusions:
- rHuGM-CSF is a valuable adjunctive therapy for managing dysmyelopoiesis and myeloid hypoplasia.
- Recommended doses of rHuGM-CSF are well-tolerated and demonstrate significant patient benefit.
- High doses of rHuGM-CSF should be avoided due to increased adverse reactions and a plateau in biological response.
More Related Videos
Related Concept Videos
Bacterial Gastroenteritis
Viral Meningitis

